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ABSTRACT 
The objective of present investigation is to design and characterise sustained release Simvastatin and immediate release of Labetalol HCl, a bi-
layer tablet. The combination therapy of Simvastatin and Labetalol HCl can be useful in severe cardiovascular disease such as hypertension, 
angina pectoris, congestive heart failure which may occur along with increasing cholesterol level in the blood, while this combination remain 
preferable choice to the patient as compared to single dosage form. The bi-layer tablet is suitable for sequential release of two drugs in 
combination which are compatible with each other. Objective of present investigation is to prepare bi-layer tablet in which one layer is sustained 
while another one is immediate release. For the preparation of bi-layer tablet, different super disintegrants like cross carmellose cellulose, micro 
crystalline cellulose is used for immediate release and HPMC and Carbapol as controlled release polymer. The pre-formulation parameter such 
as solubility, melting point, compatibility study (FTIR) were studied. Pre-compression parameter such as angle of repose, bulk density, tapped 
density, hausner’s ratio and compressibility index were studied. The tablets were evaluated by physical and chemical parameters such as weight 
uniformity, hardness, thickness, diameter, friability, drug content, disintegration time and in-vitro drug release. The dissolution data were 
subjected to various release kinetic model to recognize the mechanism of drug release. 
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1. INTRODUCTION 
Oral rout is most convenient route for administration of 
dosage form. Tablet is the convenient oral dosage form and 
acceptable by patients and physicians. Bi-layer tablet is 
suitable for sequential release of two drugs in which one is 
immediate release and another is sustained release. 
Sustained release drug delivery is the important approaches 
to achieve the controlled release of drug to obtained 
sufficient bioavailability. Hypertension and 
hypercholesterolemia frequently coexist and may require 
concomitant drug treatment.1, 2 
Simvastatin is the lipid lowering agent which is use to 
decrease the bad cholesterol level. It is potent inhibitor of 3-
hydroxy-3-methylglutaryl-coenzyme, [HMG-CoA] reductase 
which catalyzes the conversion of HMG-CoA to Mevalonate, 
an early rate determining step in cholesterol biosynthesis. 
Absorption of Simvastatin is about 85% of an oral 
administration. However because of Simvastatin is undergo 
extensive first pass metabolism and hence bioavailability is 
low is about 5%.peaak plasma concentration found to be 1.3-
2.4 hours after administration. So sustained release drug 
delivery system is suitable for Simvastatin.3 Labetalol HCl. is 
a third generation selective alpha-1-aderenergic agonist and 
non selective beta-adrenergic antagonist with vasodilatory 
and antihypertensive properties. Labetalol competitively 
bind to alpha-1-adrenergic receptor in vascular smooth 
muscle, thereby inhibiting the adrenergic stimulation of 
endothelial cell function and vasoconstriction and peripheral 
blood vessels. The result is a decrease in resting and exercise 
heart rate cardiac output and both systolic and diastolic 
blood pressure thereby resulting vasodilation and hence 
reduce the hypertension. Labetalol is completely absorbed 
(100%) from gastrointestinal tract. The half-life of Labetalol 
HCl. is approximately 4-6 hrs.4 
The combination therapy of Simvastatin and Labetalol HCl. 
may be useful and effective in serious cardiovascular disease 
such as hypertension, angina pectoris, congestive heart 
failure which may occur along with increasing cholesterol 
level in the blood, while this combination remain preferable 
choice to the patient as compared to single dosage form. The 
statin combine with antihypertensive drugs may improve the 
B.P. control in patients having obesity and hypertension.2 
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2. MATERIAL AND METHOD 
2.1. Materials:  
Simvastatin and Labetalol HCl. gifted sample (Flamingo 
pharmaceutical), HPMCK4M, Cross Carmellose Cellulose, 
Carbapol, Talc (Thermosil fine chem.) Microcrystalline 
Cellulose, Sodium Saccharine, PVPk30 (research lab) Lactose, 
(Sahyadri scientific supply) Magnesium Stearate (Hilab 
chemicals) were sample is analytical grade.5, 6 
2.2. Preparation of bi-layer tablet: 
Formulation of bilayer tablet was prepared by direct 
compression method. Immediate release layer was prepared 
by using different super disintegrants (Microcrystalline 
Cellulose, Crosscarmellose Cellulose).  
Drug and above super disintegrants were passed though the 
40# sieve and transfer into poly bag and mix up to 3 min. 
Then, other excipients added to the above mixture. Finally 
added (lubricants), Magnesium Stearate into the blend.7 
Another layer was also prepared by direct compression; 
drug and polymer (HPMCk4M, carbapol) were pass through 
the 40# sieve transfer into poly bag and mixed properly up 
to 3 min. Other excipients were mixed well and finally added 
Magnesium Stearate in above blend and were mixed for 2 
min.  
Finally above blends were compressed by rotary tablet 
compression machine (Make-CREATE INDUSTRIES, MODEL-
LP-8GMP).1, 2, 7 
Table 1: Formulation of Immediate Release of Labetalol 
HCl. 
Sr.No Ingredients  L1 L2 L3 
1 Labetalol HCl 50 50 50 
2 Lactose 20 40 60 
3 Crosscarmellose 
cellulose 
50 40 30 
4 Microcrystalline 
cellulose 
60 50 40 
5 Sodium saccharine  3 3 3 
6 Talc  9 9 9 
7 PVPk0 6 6 6 
8 Magnesium stearate  2 2 2 
Average weight of each tablet = 200 mg.
 
Table 2: Formulation of Sustained Release of Simvastatin. 
Sr.No Ingredients S1 S2 S3 S4 S5 S6 
1 Simvastatin  20 20 20 20 20 20 
2 Lactose  130 100 70 130 100 70 
3 HPMCk4M 40 70 100 - - - 
4 Carbapol - - - 40 70 100 
5 Talc 7.5 7.5 7.5 7.5 7.5 7.5 
6 Magnesium Stearate 2.5 2.5 2.5 2.5 2.5 2.5 
7 Colour q.s q.s q.s q.s q.s q.s 
Average weight of each tablet = 200 mg. 
2.3. Preformulation Study : 
2.3.1 Identification test by U.V vis. Spectrophotometer: 
a) For Labetalol HCl: 
50 mg of Labetalol Hcl was weighed accurately and 
transferred it to 50 ml volumetric flask. Dissolved it in 0.1N 
Hcl and make the volume up to 50 ml with respective 
solvent. This was considered as stock solution (1000 
mcg/ml). further dilutions were made with this stock 
solution and scanned in the range of 400-200 nm using 
respective blank in UV spectrophotometer. 
b) For Simvastatin: 
50 mg of Simvastatin was weighed accurately and 
transferred it to 50 ml volumetric flask. Dissolved it in 
Phosphate buffer (6.8pH) and make the volume up to 50 ml 
with respective solvent. This was considered as stock 
solution (1000 mcg/ml). further dilutions were made with 
this stock solution and scanned in the range of 400-200 nm 
using respective blank in UV spectrophotometer. 
2.3.2 Melting Point determination: 
The melting points of Simvastatin and Labetalol were 
determined by Melting point apparatus. The melting point 
was determined by introducing small amount of substance in 
the capillary attached to graduated thermometer. 
2.3.3 Determination of solubility:  
Qualitative Solubility  
Qualitative solubility analysis of drugs were done by 
dissolving 5 mg of drug in 5 ml solvent such as distilled 
water, methanol, ethanol, chloroform, phosphate buffer 
(7.4),ether. 
2.3.4 Compatibility study, by FT-IR spectroscopy: 
The powdered substance of the tablet were mix, dried 
potassium bromide (IR grade) ratio of sample is should be 
1:100 mg, i.e 1mg sample:100mg KBr. are compressed to 
form transparent pellets. The sample was scanned from 
4000 to 400 cm-1 at ambient temperature. 8, 9 
2.4. Pre-compression Evaluation: 
2.4.1 Bulk density: 
Bulk density was determined by placing the power blend 
into measuring cylinder and total volume was measured and 
also total powder weight was measured. The bulk density 
was calculated by using formula. 
 Bulk density (BD) = weight of powder /bulk volume. 
2.4.1 Tapped density: 
Tapped density was obtained by tapping the cylinder by 
using tapped density apparatus. Tapped the cylinder up to 
100 times and then measure the tapped volume and 
calculate the tapped density by using formula.  
Tapped Density (TD) == 
                 
              
 
2.4.3 Hausner’s ratio: 
Hausner’s ratio is the number that is correlated to the 
flowability of a powder or powder blend. it is calculated 
using formula, 
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Hausner’s ratio = 
               
             
 
2.4.4 Compressibility index: 
Compressibility index was calculated by formula, 
Carr’s index (%) = 
               –             
               
×100 
2.4.5 Angle of repose: 
The angle of repose of powder blend of each layer of each 
formulation was determined by fix funnel method. The blend 
was poured through funnel separately until apex of pile so 
formed just touch the tip of the funnel. The angle of repose 
was calculated by using formula  
  = tan-1 h/r      
h is height of pile; r is radius of pile. 
2.5 Post compression evaluation:9, 10, 11 
2.5.1. Uniformity weight: 
Average weight of the tablet was determined by selecting 
20tablet randomly. This selected tablet weighing individually 
and the weight of individual tablet was compared with 
average weight.  
Table 3: Limits for Tablet Weight variation test: 
Average weight of tablet (mg) % Difference allowed 
130 or less 10 % 
From 130 to 324 7.5 % 
> 324 5% 
 
2.5.2 Thickness: 
Thickness of the tablet was measured by using vernier 
calliper. 5 tablets were selected and thickness was measured 
in (mm).  
2.5.3. Hardness: 
Hardness is important parameter of evaluation of tablet. The 
resistance of the tablet to break under condition of handling, 
transportation and storage depend upon hardness. The 
hardness of tablet was measured by using Monsanto 
hardness tester. The unit of hardness is expressed in term of 
kg/cm2.  
2.5. 4. Friability:  
Friction and shock are the forces that most often cause 
tablets to chip, cap or break. 20 tablets are weighed and 
placed in the roche friabilator apparatus they are exposed to 
rolling and repeated shocks as they fall 6 inches in each turn 
within the apparatus. After four minutes of this treatment or 
100 revolutions, the tablets are weighed and the weight 
compared with the initial weight. The loss due to abrasion is 
a measure of the tablet friability. A maximum weight loss of 
not more than 1% of the weight of the tablets being tested 
during the friability test is considered generally acceptable 
and any broken or smashed tablets are not picked. The 
percentage friability was determined by the formula;7 
 % friability = [initial weight – final weight/initial 
weight]*100 
2.5.5. Content Uniformity:  
2.5.5.1. For Labetalol HCl: 
Tablets were taken and crushed into morter to form powder. 
From that, sample equivalent to 50 mg of drug was taken and 
transferred to 100ml volumetric flask. Methanol (20ml) was 
added and gently heated on water bath to dissolve the drug, 
cool to room temperature and volume was made up to mark 
with methanol, this was filtered. From the filterate 1ml was 
taken and diluted with pH 6.8 phosphate buffer and 
absorbance of this solution was measured by using U.V-
spectrophotometer at 302nm (SHIMADZU; U.V1800). 
2.5.5.2. For Simvastatin: 
In this test, 5 tablets were randomly selected and crushed 
into morter to form powder; sample equivalent to 20 mg was 
dissolved in 100ml of phosphate buffer pH 6.8, followed by 
stirring. The solution was filtered through a whattman filter 
paper, diluted suitably and the absorbance of resultant 
solution was measured spectrophotometrically at 247 nm 
using phosphate buffer pH 6.8 as blank. Then absorbance of 
this solution was measured by using U.V-spectrophotometer 
(SHIMADZU; U.V1800). 
2.5.6. In Vitro Drug Dissolution Studies: 
2.5.6.1. In vitro drug release was study for immediate 
release tablet (Labetalol HCl) 
In vitro drug release was studied using USP II (paddle) 
apparatus, with 900 ml of dissolution medium maintained at 
37±1°C for 15 h, at 50 rpm. 0.1 N HCl (pH 1.2).  5ml of 
sample was withdrawn in 10 min time intervals. The volume 
withdrawn at each interval was replaced with same quantity 
of fresh dissolution medium. Collected samples were 
analyzed by U.V spectrophotometrically at 302 nm, and 
cumulative percent drug release was calculate 
2.5.6.2. In vitro drug release was study for sustained 
release tablet (Simvastatin) 
The In-vitro dissolution study  for the  Simvastatin sustained 
release tablets  were carried out in USP type-II dissolution 
test apparatus (Paddle type) using 900 ml of phosphate 
buffer pH 6.8  at 50 rpm and temperature 37±0.5°C. At 
predetermined time intervals, 5 ml of the samples were 
withdrawn by means of a syringe fitted with a pre-filter, the 
volume withdrawn at each interval was replaced with same 
quantity of fresh dissolution medium. The resultant samples 
were analyzed by measuring the absorbance at 247 nm using 
UV Visible spectrophotometer and calculate the percentage 
drug release. 
2.5.6.3. In vitro drug release was study for bilayer tablet 
The release of bilayer tablets was determined using USP 
Type II (Paddle) dissolution apparatus under sink condition. 
The dissolution medium was 900 ml of a 0.1N HCl solution 
(pH=1.2), at 370c±0.20c for 1hour. Then dissolution media 
replace by phosphate buffer (6.8pH). The stirring speed was 
50 rpm. Aliquot of the solution was collected at specific 
interval were replaced with fresh dissolution medium. The 
Labetalol and Simvastatin were analyzed 
spectrophotometrically at 302 nm and 247 nm respectively 
using simultaneous equation method. 
3. RESULT AND DISCUSSION 
Pre-formulation studies:  
The UV absorption of 10 μg/ ml in 0.1N HCl (pH-1.2) for 
Labetalol HCl is 302nm  in the range of 200-400 nm exhibit 
maximum and in case of Simvastatin is at 247nm. 
Melting point, solubility and compatibility study of both drug 
are carried out and result is include in table 4 and 5. 
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Table 4: Preformulation study of Labetalol HCl 
Sr.No Parameters Observation 
1 Identification by U.V Vis spectrophotometer. 302 nm (ʎ max) 
2 Melting Point 1870c 
3 Solubility Sparingly soluble in Water and Ethanol, soluble in phosphate 
buffer, practically insoluble in ether and chloroform. 
4 Compatibility study (FTIR) Compatible. 
 
Table 5: Preformulation study of Simvastatin. 
Sr.No Parameters Observation 
1 Identification by U.V Vis spectrophotometer. 247 nm (ʎ max) 
2 Melting Point 1360c 
3 Solubility Very soluble in dichloromethane, freely soluble in ethanol, 
soluble in phosphate buffer. 
4 Compatibility study (FTIR) Compatible. 
 
 
Figure 1: FTIR of Labetalol HCl + Excepients 
 
Figure 2: FTIR of Simvastatin + Excipients 
 
Pre-compression Evaluation: 
The micromeritic properties such as of bulk density, tapped 
density, Angle of repose, compressibility index, Hausner’s 
ratio and particle size distribution of Labetalol HCl 
immediate release layer blend and Simvastatin sustained 
release layer were studied. The overall results were shown 
in Table No. 6 and 7. The value of bulk density indicates good 
packing characteristics. The compressibility index of the 
formulation Indicating a poor flow properties of powder 
which were further confirmed by determining the angle of 
repose, it is in the range of 460 to 550 which indicates poor 
flow properties. 
 
Table 6: Pre-compression evaluation of immediate release powder blend (Labetalol HCl) 
Sr. No Parameter L1 L2 L3 
1 Bulk density (g/ml) 0.3529 0.3529 0.3388 
2 Tapped density (g/ml) 0.5454 0.5454 0.6100 
3 Compressibility index (%) 35.29% 35.29% 44.54% 
4 Hausner’s ratio 1.54 1.54 1.80 
5 Angle of repose (degree) 51.110 48.990 47.200 
 
labetalol+blend 
labatelol+ blend
Name
Sample 010 By Administrator Date Thursday, November 29 2018
Sample 011 By Administrator Date Thursday, November 29 2018
Description
4000 4503500 3000 2500 2000 1500 1000 500
cm-1
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T
90
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50
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80
%
T
1 6 7 4 . 3 7 c m - 1 ,  8 . 3 0 % T
3188.59cm-1, 10.23%T
1415.66cm-1, 17.52%T
3 3 5 4 . 4 3 c m - 1 ,  1 8 . 9 8 % T
1641.04cm-1, 21.93%T
1499.36cm-1, 22.36%T
1 2 6 8 . 2 7 c m - 1 ,  2 2 . 5 7 % T
1437.59cm-1, 24.36%T1389.14cm-1, 24.41%T
3 0 6 6 . 1 5 c m - 1 ,  2 4 . 9 5 % T
1251.12cm-1, 26.74%T 823.69cm-1, 27.23%T
2981.33cm-1, 30.17%T
2802.98cm-1, 31.88%T
697.99cm-1, 32.20%T
1 5 8 0 . 6 4 c m - 1 ,  3 2 . 8 0 % T
588.30cm-1, 33.28%T1063.14cm-1, 35.30%T
2 7 5 1 . 6 5 c m - 1 ,  3 5 . 5 5 % T
1602.73cm-1, 37.16%T
666.84cm-1, 45.29%T
753.35cm-1, 45.99%T1211.91cm-1, 46.33%T
1310.87cm-1, 46.37%T
1322.68cm-1, 46.65%T
557.49cm-1, 53.21%T
452.26cm-1, 55.19%T
1035.16cm-1, 56.60%T
120.67cm-1, 58.32%T
1147.57cm-1, 59.48%T
900.16cm-1, 60.08%T
513.64cm-1, 64.87%T45.69cm-1, 64.92%T
2526.67cm-1, 68.92%T 1008.64cm-1, 71.04%T
3189.83cm-1, 31.06%T
3353.41cm-1, 33.53%T
1 0 5 9 . 4 0 c m - 1 ,  3 6 . 3 3 % T
1034.83cm-1, 36.61%T
1674.24cm-1, 37.02%T
1416.33cm-1, 39.65%T
1094.61cm-1, 41.01%T
1116.80cm-1, 41.11%T
1436.18cm-1, 42.32%T
1 3 8 8 . 8 3 c m - 1 ,  4 3 . 8 0 % T
1267.47cm-1, 44.21%T
1143.38cm-1, 44.84%T
593.68cm-1, 46.38%T1167.81cm-1, 47.75%T2900.38cm-1, 48.05%T
987.91cm-1, 48.37%T
1499.27cm-1, 49.33%T 698.40cm-1, 49.35%T
552.49cm-1, 49.36%T
667.31cm-1, 49.79%T
1641.53cm-1, 50.23%T
753.26cm-1, 50.81%T
2 9 3 4 . 3 5 c m - 1 ,  5 1 . 0 9 % T
1202.92cm-1, 51.69%T
1324.20cm-1, 52.67%T2978.04cm-1, 52.99%T 631.70cm-1, 53.60%T
1341.08cm-1, 53.78%T
822.94cm-1, 55.41%T3526.51cm-1, 56.69%T
899.26cm-1, 58.05%T
1 5 8 0 . 5 9 c m - 1 ,  5 8 . 3 8 % T
9 4 7 . 5 1 c m - 1 ,  6 0 . 3 0 % T
1603.01cm-1, 62.27%T 876.23cm-1, 64.23%T
Administrator 08
Administrator 09
Name
Sample 008 By Administrator Date Thursday, November 29 2018
Sample 009 By Administrator Date Thursday, November 29 2018
Description
4000 4503500 3000 2500 2000 1500 1000 500
cm-1
108
29
40
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90
100
%
T
89
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%
T
1697.61cm-1, 31.23%T
1710.21cm-1, 35.11%T
1267.63cm-1, 42.42%T
1 7 2 5 . 0 3 c m - 1 ,  4 2 . 5 6 % T
1165.89cm-1, 47.10%T
1226.27cm-1, 8.56%T
1073.18cm-1, 54.91%T
869.71cm-1, 55.70%T
2969.96cm-1, 57.55%T
2955.23cm-1, 57.75%T
1055.59cm-1, 58.47%T
2930.08cm-1, 61.01%T 1246.35cm-1, 61.36%T
1043.62cm-1, 65.12%T
1390.31cm-1, 66.45%T3 5 5 1 . 0 5 c m - 1 ,  6 6 . 6 4 % T
2871.61cm-1, 70.45%T 1369.15cm-1, 71.49%T
2884.94cm-1, 72.54%T
1467.86cm-1, 74.76%T 1116.04cm-1, 75.27%T
1450.05cm-1, 77.82%T
1126.48cm-1, 78.43%T
1347.11cm-1, 81.77%T3011.37cm-1, 82.72%T
974.82cm-1, 84.03%T1312.26cm-1, 84.20%T
968.05cm-1, 84.45%T
754.76cm-1, 84.72%T
577.92cm-1, 85.29%T
1010.93cm-1, 86.62%T
738.18cm-1, 87.18%T
799.97cm-1, 87.45%T
1103.09cm-1, 87.92%T
991.01cm-1, 89.13%T
487.45cm-1, 93.13%T774.64cm-1, 93.33%T
920.82cm-1, 93.67%T
652.75cm-1, 94.24%T
940.05cm-1, 94.37%T
842.70cm-1, 95.33%T
699.08cm-1, 95.45%T
895.41cm-1, 96.18%T
624.61cm-1, 97.68%T
1035.55cm-1, 21.92%T
1072.15cm-1, 22.10%T
1094.46cm-1, 24.42%T
1057.68cm-1, 25.24%T
1115.94cm-1, 26.69%T3381.14cm-1, 27.08%T
1083.43cm-1, 27.10%T
3 3 4 1 . 9 6 c m - 1 ,  2 7 . 7 7 % T 1019.62cm-1, 28.16%T
1167.29cm-1, 30.39%T114 .65cm-1, 30.5 %T
988.42cm-1, 37.81%T
3527.62cm-1, 38.03%T
2900.38cm-1, 40.88%T
1202.05cm-1, 42.43%T
2932.94cm-1, 43.48%T 551.70cm-1, 43.55%T1 2 6 2 . 6 9 c m - 1 ,  4 3 . 7 3 % T
1341.72cm-1, 45.10%T
605.01cm-1, 45.20%T
1382.69cm-1, 45.22%T
1221.80cm-1, 45.46%T1368.09cm-1, 45.73%T
631.93cm-1, 45.74%T
778.40cm-1, 45.97%T
1 4 2 4 . 5 2 c m - 1 ,  4 6 . 3 7 % T
755.14cm-1, 46.82%T
577.35cm-1, 48.99%T
669.99cm-1, 50.02%T2976.47cm-1, 51.70%T
468.32cm-1, 53.62%T
1295.84cm-1, 54.35%T
1697.71cm-1, 55.19%T
899.24cm-1, 56.00%T
875.68cm-1, 56.52%T
915.71cm-1, 61.24%T
1645.84cm-1, 65.21%T
1583.14cm-1, 71.71%T
2066.96cm-1, 84.13%T
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Table 7: Pre-compression evaluation of sustained release powder blend (Simvastatin) 
S.N. Parameter S1 S2 S3 S4 S5 S6 
1 Bulk density(g/ml) 0.30 0.36 0.34 0.35 0.32 0.30 
2 Tapped density(g/ml) 0.75 0.70 0.73 0.64 0.62 0.60 
3 Compressibility Index (%) 60 57.14 53.42 45.31 48.38 50 
4 Hausner’s ratio 2.5 1.94 2.14 1.82 1.9 2 
5 Angle of repose(degree) 50.19 50.65 47.20 47.64 45.34 42.61 
 
Post-compression Evaluation of Tablet:  
The prepared tablets were evaluated for weight variation, 
dissolution test, thickness, hardness uniformity of dosage 
units and friability. The weight variation test is done by 
weighing 20 tablets individually, calculating the average 
weight and comparing the individual weights to the average.  
The hardness of each batch of tablet was checked by using 
Monsanto hardness tester. The hardness was measured in 
terms of kg/cm2. The hardness of 6 tablets was determined 
using  
The Friability was determined by first weighing 10 tablets 
after dusting and placing them in a friability tester (Roche 
friabilator), which was rotated for 4 min at 25 rpm. After 
dusting, the total remaining mass of tablet was recorded and 
the percent friability was calculated. 
The thickness of the each 10 tablets was measured with the 
Varnier Caliper. All test value are include in table no 8   
Drug content uniformity determined according to the USP 
requirements. Test values are include in table no 9 and 10. 
In vitro Dissolution Study 
The in-vitro dissolution characteristics of Labetalol HCl and 
Simvastatin bilayer tablets are shown Table No.11and 12.  
Based on the in-vitro release profile of drug formulations of  
L1 to L3, for Labetalol. The formulation of sustained release 
layer Simvastatin S6 showed better drug release, which was 
achieved by increasing the polymer concentration of 
carbapol increase the release rate. 
 
Table 8: Post-compression Evaluation of Tablet 
Sr.No Parameter B1 B2 B3 B4 B5 B6 
1 Uniformity weight(mg) 405.7 410.02 399.8 403.1 399.6 405.7 
2 Thickness(mm) 3.00 3.00 3.00 3.00 3.00 3.00 
3 Hardness(kg/cm2) 5 5.2 5 5 5.5 5 
4 Friability(%) 0.1863 0.2056 0.2032 0.2447 0.2788 0.1977 
 
Table9: Drug content of Immediate Release Layer (Labetalol HCl.) 
Sr. No Parameter L1% L2% L3% 
1 Drug Content (%) 99.8 96.50 101.2 
 
Table 10:  Drug content of sustained release layer (Simvastatin) 
S. No Parameter S1 %  S2 %  S3 %  S4 %  S5 %  S6 %  
1 Drug Content (%) 99.60 98.20 91.85 97.28 98.52 99.85 
 
Table 11: Percentage drugs release of immediate release layer (Labetalol HCl.) 
Time in (min) L1 % Release L3 % Release L3 % Release 
10 20.28 19.29 26.76 
20 36.96 33.68 47.86 
30 46.92 61.7 59.84 
40 66.92 81.68 74.64 
50 83.53 87.19 91.04 
60 97.02 93.38 98.22 
 
Table 12: Percentage drugs release sustained release layer (Simvastatin) 
time in hours) S1 % Release S2 % Release S3 % Release S4 % Release S5 % Release S6 % Release 
1 29.74 16.8 7.29 8.76 5.17 3.807 
2 36.94 20.17 18.27 10.16 5.99 9.097 
3 37.26 23.3 19.84 10.69 6.92 11.27 
4 37.12 29.89 20.47 11.58 8.45 14.35 
5 39.82 40.95 26.73 15.31 13.63 27.11 
6 42.43 46.27 35.41 29.47 26.25 40.83 
7 47.16 54.18 36.72 40.69 38.6 48.98 
8 77.22 85.31 39.91 46.95 43.37 58.09 
9 83.33 85.94 52.45 52.45 61.2 70.5 
10 87.68 86.35 70.1 61.62 74.94 88.98 
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Figure 3: In-vitro dissolution of immediate release layer 
of Labetalol HCl 
 
Figure 4: In-vitro dissolution of sustained release layer 
of Simvastatin 
Table13: in-vitro dissolution bi-layered tablet Labetalol 
HCl and Simvastatin. 
time 
(min) % drug release Labetalol 
% release 
Simvastatin 
10 30.3  - 
20 47.89  - 
30 58.99  - 
40 75.94  - 
50 93.25  - 
60 98.22  - 
60  - 2.8 
120  - 6.09 
180  - 11.27 
240  - 15.31 
300  - 26.73 
360  - 39.91 
420  - 61.2 
480  - 69.4 
540  - 75.2 
600  - 87.94 
 
 
Figure 5: in-vitro dissolution bi-layered tablet Labetalol 
HCl and Simvastatin. 
Kinetic Models: 
Dissolution data of above bi-layered tablet was fitted in Zero 
order, First order and Higuchi equations. The mechanism of 
drug release was determined by using Higuchi equation.
 
Table13: Drug release kinetics of Labetalol. 
Time  
(min) 
cumulative % 
drug released 
% drug 
remaining 
Square 
root 
time 
log Cumu % 
drug 
remainining 
log 
time 
log Cumu % 
drug 
released 
% Drug 
released 
Cube Root of 
% drug 
Remaining 
(Wt) 
Wo-
Wt 
0 0 100 0.000 2.000 0.000 0.000 100 4.642 0.000 
10 30.3 69.7 3.162 1.843 1.000 1.481 30.3 4.115 0.527 
20 47.89 52.11 4.472 1.717 1.301 1.680 17.59 3.735 0.907 
30 58.99 41.01 5.477 1.613 1.477 1.771 11.1 3.448 1.194 
40 75.94 24.06 6.325 1.381 1.602 1.880 16.95 2.887 1.755 
50 93.25 6.75 7.071 0.829 1.699 1.970 17.31 1.890 2.752 
60 98.22 1.78 7.746 0.250 1.778 1.992 4.97 1.212 3.430 
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Table 14: Drug release kinetics of Simvastatin. 
Time 
(Hr) 
cumulativ
e % drug 
released 
% drug 
remainin
g 
Square 
root 
time 
log Cumu % 
drug 
remaininin
g 
log 
time 
log 
Cumu 
% drug 
release
d 
% Drug 
release
d 
Cube Root of 
% drug 
Remaining(Wt
) Wo-Wt 
0 0 100 0.000 2.000 0.000 0.000 100 4.642 0.000 
1 2.8 97.2 1.000 1.988 0.000 0.447 2.8 4.598 0.044 
2 6.09 93.91 1.414 1.973 0.301 0.785 3.29 4.545 0.097 
3 11.27 88.73 1.732 1.948 0.477 1.052 5.18 4.460 0.182 
4 15.31 84.69 2.000 1.928 0.602 1.185 4.04 4.391 0.251 
5 26.73 73.27 2.236 1.865 0.699 1.427 11.42 4.184 0.458 
6 39.91 60.09 2.449 1.779 0.778 1.601 13.18 3.917 0.725 
7 61.2 38.8 2.646 1.589 0.845 1.787 21.29 3.385 1.257 
8 69.4 30.6 2.828 1.486 0.903 1.841 8.2 3.128 1.514 
9 75.2 24.8 3.000 1.394 0.954 1.876 5.8 2.916 1.726 
10 87.94 12.06 3.162 1.081 1.000 1.944 12.74 2.293 2.349 
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4. CONCLUSION 
The prepared tablets showed satisfactory results for various 
evaluation tests such as tablet dimension, hardness, 
friability, weight uniformity, drug content and in-vitro 
dissolution study. The optimized formulation based on all 
the parameter L3 (cross carmellose cellulose) is selected for 
immediate release layer and S6 (carbapol) was selected for 
controlled release layer. The drug release mechanism was 
found to be zero order release; dependent on both drug 
diffusion and polymer relaxation. The bilayer tablets of 
Labetalol and Simvastatin may be useful in serious 
cardiovascular adverse effect such as hypertension, 
congestive heart failure and exacerbation of angina. 
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